[
  {
    "ts": null,
    "headline": "Pfizer CEO discusses the company's GLP-1 weigh-loss drug pipeline",
    "summary": "Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical giant's progress in developing a GLP-1 weight-loss drug and its current injectable product portfolio. Also catch Yahoo Finance's full interview with Albert Bourla. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=0a02ab49e33e8decd03c2a988e9a2152de7aa4e1faae3c9aad56b7bb72a179f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770469250,
      "headline": "Pfizer CEO discusses the company's GLP-1 weigh-loss drug pipeline",
      "id": 138384977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical giant's progress in developing a GLP-1 weight-loss drug and its current injectable product portfolio. Also catch Yahoo Finance's full interview with Albert Bourla. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=0a02ab49e33e8decd03c2a988e9a2152de7aa4e1faae3c9aad56b7bb72a179f7"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  },
  {
    "ts": null,
    "headline": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (February 2026)",
    "summary": "Read the latest article in our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms.",
    "url": "https://finnhub.io/api/news?id=30c5616273b90ece4a037f60c3885635a35299c037515bbf85fea9969e1a0198",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770452400,
      "headline": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (February 2026)",
      "id": 138384798,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249993252/image_1249993252.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read the latest article in our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms.",
      "url": "https://finnhub.io/api/news?id=30c5616273b90ece4a037f60c3885635a35299c037515bbf85fea9969e1a0198"
    }
  },
  {
    "ts": null,
    "headline": "What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders",
    "summary": "Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% placebo-adjusted weight loss at 28 weeks and confirming a safety profile consistent with the GLP-1 class. The company now plans more than 20 obesity-related studies in 2026, including 10 Phase 3 trials of PF-3944, underscoring how central obesity treatments have become to Pfizer’s pipeline. We’ll now examine how Pfizer’s push into monthly GLP-1 obesity therapy shapes its...",
    "url": "https://finnhub.io/api/news?id=a4877ba65ea7ac41c70416cd635d7d462c72e659ed2c2c66aa6990072a76d3d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770440812,
      "headline": "What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders",
      "id": 138382760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% placebo-adjusted weight loss at 28 weeks and confirming a safety profile consistent with the GLP-1 class. The company now plans more than 20 obesity-related studies in 2026, including 10 Phase 3 trials of PF-3944, underscoring how central obesity treatments have become to Pfizer’s pipeline. We’ll now examine how Pfizer’s push into monthly GLP-1 obesity therapy shapes its...",
      "url": "https://finnhub.io/api/news?id=a4877ba65ea7ac41c70416cd635d7d462c72e659ed2c2c66aa6990072a76d3d3"
    }
  }
]